Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P62988 (
Ubiquitin
)
4,326
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Uch37 is one of the three principal deubiquitinating enzymes (DUBs), and the only
ubiquitin carboxy-terminal hydrolase
(UCH)-family protease, that is associated with mammalian proteasomes. We show that Uch37 is responsible for the ubiquitin isopeptidase activity in the PA700 (19S) proteasome regulatory complex. PA700 isopeptidase disassembles Lys 48-linked
polyubiquitin
specifically from the distal end of the chain, a property that may be used to clear poorly ubiquitinated or unproductively bound substrates from the proteasome. To better understand Uch37 function and the mechanism responsible for its specificity, we investigated how Uch37 is recruited to proteasomes. Uch37 binds through Adrm1, a previously unrecognized orthologue of Saccharomyces cerevisiae Rpn13p, which in turn is bound to the S1 (also known as Rpn2) subunit of the 19S complex. Adrm1 (human Rpn13, hRpn13) binds the carboxy-terminal tail of Uch37, a region that is distinct from the UCH catalytic domain, which we show inhibits Uch37 activity. Following binding, Adrm1 relieves Uch37 autoinhibition, accelerating the hydrolysis of ubiquitin-7-amido-4-methylcoumarin (ubiquitin-AMC). However, neither Uch37 alone nor the Uch37-Adrm1 or Uch37-Adrm1-S1 complexes can hydrolyse di-ubiquitin efficiently; rather, incorporation into the 19S complex is required to enable processing of
polyubiquitin
chains.
...
PMID:Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. 1690 46
The breast and ovarian tumor suppressor BRCA1 constitutes a RING heterodimer E3 ligase with BARD1.
BRCA1-associated protein 1
(
BAP1
) is a ubiquitin COOH-terminal hydrolase that was initially identified as a protein that bound to the RING finger domain of BRCA1. However, how
BAP1
contributes to the E3 activity of BRCA1/BARD1 is unclear. Here, we report that
BAP1
interacts with BARD1 to inhibit the E3 ligase activity of BRCA1/BARD1. Domains comprised by residues 182-365 of
BAP1
interact with the RING finger domain of BARD1, and surface plasmon resonance spectroscopy (BIAcore) analyses showed that
BAP1
interferes with the BRCA1/BARD1 association. The perturbation resulted in inhibition of BRCA1 autoubiquitination and NPM1/B23 ubiquitination by BRCA1/BARD1. Although
BAP1
was capable of deubiquitinating the
polyubiquitin
chains mediated by BRCA1/BARD1 in vitro, a catalytically inactive mutant of
BAP1
, C91S, still inhibited the ubiquitination in vitro and in vivo, implicating a second mechanism of action. Importantly, inhibition of
BAP1
expression by short hairpin RNA resulted in hypersensitivity of the cells to ionizing irradiation and in retardation of S-phase progression. Together, these results suggest that
BAP1
and BRCA1/BARD1 coordinately regulate ubiquitination during the DNA damage response and the cell cycle.
...
PMID:BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. 1911 93
The deubiquitinating enzyme
BRCA1-associated protein 1
(
BAP1
) possesses growth inhibitory activity and functions as a tumor suppressor. In this study we report that
BAP1
also plays positive roles in cell proliferation.
BAP1
depletion by RNAi inhibits cell proliferation as does overexpression of a dominant negative mutant of
BAP1
. Mass spectrometry analyses of copurified proteins revealed that
BAP1
is associated with factors involved in chromatin modulation and transcriptional regulation. We show that the interaction with host cell factor-1 (HCF-1), a cell-cycle regulator composed of HCF-1N and HCF-1C, is critical for the
BAP1
-mediated growth regulation. We found that HCF-1N is modified with Lys-48-linked
polyubiquitin
chains on its Kelch domain. The HCF-1 binding motif of
BAP1
is required for interaction with HCF-1N and mediates deubiquitination of HCF-1N by
BAP1
. The importance of the
BAP1
-HCF-1 interaction is underscored by the fact that growth suppression by the dominant negative
BAP1
mutant is entirely dependent on the HCF-1 binding motif. These results suggest that
BAP1
regulates cell proliferation by deubiquitinating HCF-1.
...
PMID:The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. 1981 55
Ubiquitin carboxy-terminal hydrolase L5 (UCHL5) is a proteasome-associated deubiquitinating enzyme, which, along with RPN11 and USP14, is known to carry out deubiquitination on proteasome. As a member of the
ubiquitin carboxy-terminal hydrolase
(UCH) family, UCHL5 is unusual because, unlike UCHL1 and UCHL3, it can process
polyubiquitin
chain. However, it does so only when it is bound to the proteasome; in its free form, it is capable of releasing only relatively small leaving groups from the C-terminus of ubiquitin. Such a behavior might suggest at least two catalytically distinct forms of the enzyme, an apo form incapable of chain processing activity, and a proteasome-induced activated form capable of cleaving
polyubiquitin
chain. Through the crystal structure analysis of two truncated constructs representing the catalytic domain (UCH domain) of this enzyme, we were able to visualize a state of this enzyme that we interpret as its inactive form, because the catalytic cysteine appears to be in an unproductive orientation. While this work was in progress, the structure of a different construct representing the UCH domain was reported; however, in that work the structure reported was that of an inactive mutant [catalytic Cys to Ala; Nishio K et al. (2009) Biochem Biophys Res Commun 390, 855-860], which precluded the observation that we are reporting here. Additionally, our structures reveal conformationally dynamic parts of the enzyme that may play a role in the structural transition to the more active form.
...
PMID:Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme. 2199 38
The gracile axonal dystrophy (gad) mutation in Uch-l1, the gene encoding the
ubiquitin carboxy-terminal hydrolase
isozyme L1 (UCH-L1), causes selective dying back degeneration of dorsal root ganglion neuron in the medulla oblongata along with progressive sensory-motor ataxia. Axonal spheroids are observed within degenerating axons, and their contents may illuminate the pathogenic mechanisms leading to neurodegeneration in gad mice. To analyze changes in negatively charged lipid molecules in dystrophic axons of gad mice, we performed matrix-assisted laser desorption/ionization (MALDI)-imaging mass spectrometry (IMS), electron microscopy, and fluorescence immunohistochemistry on tissue sections from gad and wild-type mouse medulla. MALDI-IMS revealed that m/z 806.68 and 822.68 molecules, assigned to sulfatide (ST) C18:0 and ST C18:0(OH), respectively, were concentrated in the dorsomedial medulla. This spatial distribution overlapped significantly with that of axonal spheroids. Immunostaining revealed that spheroids accumulated myelin and lymphocyte protein, a known ST binding protein. Sulfatides with short-chain fatty acids (C16-C20) are generally localized in intracellular vesicles; therefore, ST C18:0 accumulation may reflect intracellular vesicle aggregation within spheroids.
Ubiquitin
system disruption apparently alters lipid metabolism, membrane organization, protein turnover, and axonal transport. Changes in membrane organization, particularly STs within lipid rafts, may disrupt cellular signaling pathways necessary for neuronal viability.
...
PMID:Sulfatide accumulation in the dystrophic terminals of gracile axonal dystrophy mice: lipid analysis using matrix-assisted laser desorption/ionization imaging mass spectrometry. 2341 24